Overview

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Seagen Inc.
Seattle Genetics, Inc.
Treatments:
Antibodies, Monoclonal
Brentuximab Vedotin